+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Diabetes Devices Market Size, Share & Trends Analysis Report by Product (BGM Devices, Insulin Delivery Devices) by Distribution Channel, by End Use (Hospitals, Homecare), by Region, and Segment Forecasts, 2020 - 2027

  • ID: 4599560
  • Report
  • March 2020
  • Region: Global
  • 110 pages
  • Grand View Research
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott Laboratories
  • B Braun Melsungen AG
  • Dexcom Inc.
  • Insulet Corporation
  • Medtronic Plc
  • Sanofi
  • MORE
The global diabetes devices market size is expected to reach USD 41.6 billion by 2027, registering a CAGR of 7.8% over the forecast period. The market is driven by factors such as increasing incidence of diabetes, technological advancements, and innovative product launches. Increasing adoption of advanced diabetes management solutions in developing region, government policies, and rising medical tourism are some of the major factors contributing to the market growth. Furthermore, rising government initiatives to spread awareness about diabetes and increasing R&D expenditure of major players are the factors expected to boost market growth.

According to a study published on National Center for Biotechnology Information (NCBI), global health expenditure on diabetes is expected to reach USD 490 billion in 2030 from 376 billion in 2010. Obesity, sedentary lifestyle, and fast food culture are some of the factors expected to have significant impact on the market growth. According to Harvard T.H. Chan School of Public Health, U.S. has the highest rates of obesity and it is expected to increase up to 50% by 2030.

In addition, increasing number of new market players, who focus on patient convenience with the help of artificial intelligence technology, are also transforming the market. They are leveraging technological advancements to improve diabetes care solutions like CGM devices, non-invasive insulin delivery systems, and digital diabetes management platforms. For instance, in December 2017, Companion Medical Launched Inpen, its first smart insulin pen system in the U.S. It is the only FDA approved device that can combine insulin injector pen with a smart app.

Further key findings from the report suggest:
  • North America accounted for the largest share in 2019, in terms of revenue, owing to favorable reimbursement policies, presence of key players, and frequent product launches
  • By product, the insulin delivery devices segment accounted for the largest market share and is also expected to grow at the fastest rate
  • In the Blood Glucose Monitoring (BGM) segment, self-monitoring devices dominated the market owing to their low cost and high usage
  • In Self-monitoring of Blood Glucose (SMBG) devices, testing strips segment dominated the market while blood glucose meters are expected to grow at a significant pace owing to high adoption and technological advancements
  • In the Continuous Glucose Monitoring (CGM) devices segment, transmitters accounted for the largest share owing to high cost of devices and high usage
  • In insulin delivery devices, pens segment dominated the market since it is easy to carry, easy to use, and has low cost as compared to other delivery devices
  • By distribution channel, hospital pharmacy segment dominated the market owing to rise in sales of diabetes devices in these pharmacies
  • By end use, hospital segment accounted for the largest market share owing to improving healthcare infrastructure due to rising investment
  • The leading players present in the diabetes devices market are Medtronic plc, Abbott Laboratories, F.Hoffmann-La-Ltd, Bayer AG, Lifescan, Inc., B Braun Melsungen AG, Lifescan, Inc., Dexcom Inc., Insulet Corporation, Ypsomed Holdings, Companion Medical, Sanofi, Valeritas Holding Inc., Novo Nordisk, Arkray, Inc., among others.

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • B Braun Melsungen AG
  • Dexcom Inc.
  • Insulet Corporation
  • Medtronic Plc
  • Sanofi
  • MORE
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Distribution Channels Type
1.1.3. End Use Type
1.1.4. Region scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. Internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product Outlook
2.2.2. Regional outlook
2.3. Competitive Insights

Chapter 3. Diabetes Devices Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.3.1. Reimbursement framework
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.1.1. Rising prevalence of diabetes
3.4.1.2. Increasing geriatric population
3.4.1.3. Technological advancement in Diabetes Devices
3.4.1.4. Rising awareness about diabetes preventive care
3.4.2. Market restraint analysis
3.4.2.1. Low per capita expenditure on diabetes
3.4.2.2. Lack of reimbursement and stringent regulations in few countries
3.4.3. Industry challenges
3.5. Diabetes Devices Market Analysis Tools
3.5.1. Industry analysis - Porter’s
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic landscape
3.5.3. Major deals & strategic alliances analysis
3.5.4. Market entry strategies

Chapter 4. Diabetes Devices Market by Product Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. BGM Devices
4.1.1.1. Self-Monitoring devices
4.1.1.1.1. Blood Glucose Meter
4.1.1.1.2. Testing Strips
4.1.1.1.3. Lancets
4.1.1.2. Continuous Glucose Monitoring Devices
4.1.1.2.1. Sensors
4.1.1.2.2. Transmitters
4.1.1.2.3. Receiver
4.1.2. Insulin Delivery Devices
4.1.2.1. Pumps
4.1.2.2. Pens
4.1.2.3. Syringes
4.1.2.4. Jet Injectors
4.2. Product Market Share, 2019 & 2027
4.3. Segment Dashboard
4.4. Global Diabetes Devices Market by Product Outlook
4.4.1. BGM Devices
4.4.1.1. Self-Monitoring Device
4.4.1.1.1. Market estimates and forecast, 2016 - 2027 (USD Million)
4.4.1.1.2. Blood glucose meter
4.4.1.1.2.1. Market estimates and forecast, 2016 - 2027 (USD Million)
4.4.1.1.3. Testing strips
4.4.1.1.3.1. Market estimates and forecast, 2016 - 2027 (USD Million)
4.4.1.1.4. Lancets
4.4.1.1.4.1. Market estimates and forecast, 2016 - 2027 (USD Million)
4.4.1.2. Continuous glucose monitoring devices
4.4.1.2.1. Market estimates and forecast, 2016 - 2027 (USD Million)
4.4.1.2.2. Sensors
4.4.1.2.2.1. Market estimates and forecast, 2016 - 2027 (USD Million)
4.4.1.2.3. Transmitters
4.4.1.2.3.1. Market estimates and forecast, 2016 - 2027 (USD Million)
4.4.1.2.4. Receiver
4.4.1.2.4.1. Market estimates and forecast, 2016 - 2027 (USD Million)
4.4.1.3. Insulin delivery devices
4.4.1.3.1. Pens
4.4.1.3.1.1. Market estimates and forecast, 2016 - 2027 (USD Million)
4.4.1.3.2. Pumps
4.4.1.3.2.1. Market estimates and forecast, 2016 - 2027 (USD Million)
4.4.1.3.3. Syringes
4.4.1.3.3.1. Market estimates and forecast, 2016 - 2027 (USD Million)
4.4.1.3.4. Jet Injectors
4.4.1.3.4.1. Market estimates and forecast, 2016 - 2027 (USD Million)

Chapter 5. Diabetes Devices Market: Distribution Channel Estimates & Trend Analysis
5.1. Definitions and Scope
5.1.1. Hospital Pharmacies
5.1.2. Retail Pharmacies
5.1.3. Diabetes Clinics/ Centers
5.1.4. Online Pharmacies
5.1.5. Others
5.2. Product Market Share, 2019 & 2027
5.3. Segment Dashboard
5.4. Global Diabetes Devices Market by Distribution Channel Outlook
5.4.1. Hospital Pharmacies
5.4.1.1. Market estimates and forecast, 2016 - 2027 (USD Million)
5.4.2. Retail Pharmacies
5.4.2.1. Market estimates and forecast, 2016 - 2027 (USD Million)
5.4.3. Diabetes Clinics/Centers
5.4.3.1. Market estimates and forecast, 2016 - 2027 (USD Million)
5.4.4. Online Pharmacies
5.4.4.1. Market estimates and forecast, 2016 - 2027 (USD Million)
5.4.5. Others
5.4.5.1. Market estimates and forecast, 2016 - 2027 (USD Million)

Chapter 6. Diabetes Devices Market: End Use Estimates & Trend Analysis
6.1. Definitions and Scope
6.1.1. Hospitals
6.1.2. Homecare
6.1.3. Diagnostic Centers
6.2. Product Market Share, 2019 & 2027
6.3. Segment Dashboard
6.4. Global Diabetes Devices Market by End Use Channel Outlook
6.4.1. Hospitals
6.4.1.1. Market estimates and forecast, 2016 - 2027 (USD Million)
6.4.2. Homecare
6.4.2.1. Market estimates and forecast, 2016 - 2027 (USD Million)
6.4.3. Diagnostic Centers
6.4.3.1. Market estimates and forecast, 2016 - 2027 (USD Million)

Chapter 7. Diabetes Devices Market: Country Estimates & Trend Analysis
7.1. Country Market Share Analysis, 2019 & 2027
7.2. County Market Dashboard
7.3. Regional Market Snapshot
7.4. Regional Market Share and Leading Players, 2019
7.4.1. North America
7.4.2. Europe
7.4.3. Asia Pacific
7.4.4. Latin America
7.4.5. Middle East and Africa
7.5. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
7.5.1. North America
7.5.2. Europe
7.5.3. Asia Pacific
7.5.4. Latin America
7.5.5. Middle East and Africa
7.6. Market Size, & Forecasts, Volume and Trend Analysis, 2019 to 2027:
7.7. North America
7.7.1. Market estimates and forecast, 2016 - 2027 (USD Million)
7.7.2. U.S.
7.7.2.1. U.S. market estimates and forecast, 2016 - 2027 (USD Million)
7.7.3. Canada
7.7.3.1. Canada market estimates and forecast, 2016 - 2027 (USD Million)
7.8. Europe
7.8.1. Market estimates and forecast, 2016 - 2027 (USD Million)
7.8.2. U.K.
7.8.2.1. U.K. market estimates and forecast, 2016 - 2027 (USD Million)
7.8.3. Germany
7.8.3.1. Germany market estimates and forecast, 2016 - 2027 (USD Million)
7.8.4. France
7.8.4.1. France market estimates and forecast, 2016 - 2027 (USD Million)
7.8.5. Italy
7.8.5.1. Italy market estimates and forecast, 2016 - 2027 (USD Million)
7.8.6. Spain
7.8.6.1. Spain market estimates and forecast, 2016 - 2027 (USD Million)
7.8.7. Czech Republic
7.8.7.1. Czech Republic market estimates and forecast, 2016 - 2027 (USD Million)
7.8.8. Russia
7.8.8.1. Russia market estimates and forecast, 2016 - 2027 (USD Million)
7.8.9. Poland
7.8.9.1. Poland market estimates and forecast, 2016 - 2027 (USD Million)
7.8.10. Turkey
7.8.10.1. Turkey market estimates and forecast, 2016 - 2027 (USD Million)
7.8.11. Switzerland
7.8.11.1. Switzerland market estimates and forecast, 2016 - 2027 (USD Million)
7.9. Asia Pacific
7.9.1. Market estimates and forecast, 2016 - 2027 (USD Million)
7.9.2. Japan
7.9.2.1. Japan market estimates and forecast, 2016 - 2027 (USD Million)
7.9.3. China
7.9.3.1. China market estimates and forecast, 2016 - 2027 (USD Million)
7.9.4. India
7.9.4.1. India market estimates and forecast, 2016 - 2027 (USD Million)
7.9.5. Australia
7.9.5.1. Australia market estimates and forecast, 2016 - 2027 (USD Million)
7.9.6. South Korea
7.9.6.1. South Korea market estimates and forecast, 2016 - 2027 (USD Million)
7.9.7. Vietnam
7.9.7.1. Vietnam market estimates and forecast, 2016 - 2027 (USD Million)
7.9.8. Philippines
7.9.8.1. Philippines market estimates and forecast, 2016 - 2027 (USD Million)
7.9.9. Malaysia
7.9.9.1. Malaysia market estimates and forecast, 2016 - 2027 (USD Million)
7.9.10. Indonesia
7.9.10.1. Indonesia market estimates and forecast, 2016 - 2027 (USD Million)
7.9.11. Thailand
7.9.11.1. Thailand market estimates and forecast, 2016 - 2027 (USD Million)
7.10. Latin America
7.10.1. market estimates and forecast, 2016 - 2027 (USD Million)
7.10.2. Brazil
7.10.2.1. Brazil market estimates and forecast, 2016 - 2027 (USD Million)
7.10.3. Mexico
7.10.3.1. Mexico market estimates and forecast, 2016 - 2027 (USD Million)
7.10.4. Colombia
7.10.4.1. Colombia market estimates and forecast, 2016 - 2027 (USD Million)
7.10.5. Argentina
7.10.5.1. Argentina market estimates and forecast, 2016 - 2027 (USD Million)
7.10.6. Chile
7.10.6.1. Chile market estimates and forecast, 2016 - 2027 (USD Million)
7.11. Middle East & Africa
7.11.1. Market estimates and forecast, 2016 - 2027 (USD Million)
7.11.2. South Africa
7.11.2.1. South Africa market estimates and forecast, 2016 - 2027 (USD Million)
7.11.3. Saudi Arabia
7.11.3.1. Saudi Arabia market estimates and forecast, 2016 - 2027 (USD Million)
7.11.4. UAE
7.11.4.1. UAE market estimates and forecast, 2016 - 2027 (USD Million)
7.11.5. Oman
7.11.5.1. Oman market estimates and forecast, 2016 - 2027 (USD Million)
7.11.6. Egypt
7.11.6.1. Egypt market estimates and forecast, 2016 - 2027 (USD Million)

Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.2.1. Innovators
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2019
8.3.4. Medtronic Plc
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Procedure benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Abbott Laboratories
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Procedure benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Arkray, Inc
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Procedure benchmarking
8.3.6.4. Strategic initiatives
8.3.7. B Braun Melsungen AG
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Procedure benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Bayer Corporation
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Procedure benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Dexcom Inc.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Procedure benchmarking
8.3.9.4. Strategic initiatives
8.3.10. F Hoffmann-La Roche Ag
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Procedure benchmarking
8.3.10.4. Strategic initiatives
8.3.11. LifeScan, Inc
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Procedure benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Sanofi
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Procedure benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Insulet Corporation
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Procedure benchmarking
8.3.13.4. Strategic initiatives
8.3.14. Novo Nordisk
8.3.14.1. Company overview
8.3.14.2. Financial performance
8.3.14.3. Procedure benchmarking
8.3.14.4. Strategic initiatives
8.3.15. Ypsomed Holding AG
8.3.15.1. Company overview
8.3.15.2. Financial performance
8.3.15.3. Procedure benchmarking
8.3.15.4. Strategic initiatives
8.3.16. Valeritas Holdings Inc.
8.3.16.1. Company overview
8.3.16.2. Financial performance
8.3.16.3. Procedure benchmarking
8.3.16.4. Strategic initiatives
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Medtronic Plc
  • Abbott Laboratories
  • Arkray, Inc
  • B Braun Melsungen AG
  • Bayer Corporation
  • Dexcom Inc.
  • F Hoffmann-La Roche Ag
  • LifeScan, Inc
  • Sanofi
  • Insulet Corporation
  • Novo Nordisk
  • Ypsomed Holding AG
  • Valeritas Holdings Inc.
Note: Product cover images may vary from those shown
Adroll
adroll